Literature DB >> 17124408

Whole-genome array-CGH screening in undiagnosed syndromic patients: old syndromes revisited and new alterations.

A C V Krepischi-Santos1, A M Vianna-Morgante, F S Jehee, M R Passos-Bueno, J Knijnenburg, K Szuhai, W Sloos, J F Mazzeu, F Kok, C Cheroki, P A Otto, R C Mingroni-Netto, M Varela, C Koiffmann, C A Kim, D R Bertola, P L Pearson, C Rosenberg.   

Abstract

We report array-CGH screening of 95 syndromic patients with normal G-banded karyotypes and at least one of the following features: mental retardation, heart defects, deafness, obesity, craniofacial dysmorphisms or urogenital tract malformations. Chromosome imbalances not previously detected in normal controls were found in 30 patients (31%) and at least 16 of them (17%) seem to be causally related to the abnormal phenotypes. Eight of the causative imbalances had not been described previously and pointed to new chromosome regions and candidate genes for specific phenotypes, including a connective tissue disease locus on 2p16.3, another for obesity on 7q22.1-->q22.3, and a candidate gene for the 3q29 deletion syndrome manifestations. The other causative alterations had already been associated with well-defined phenotypes including Sotos syndrome, and the 1p36 and 22q11.21 microdeletion syndromes. However, the clinical features of these latter patients were either not typical or specific enough to allow diagnosis before detection of chromosome imbalances. For instance, three patients with overlapping deletions in 22q11.21 were ascertained through entirely different clinical features, i.e., heart defect, utero-vaginal aplasia, and mental retardation associated with psychotic disease. Our results demonstrate that ascertainment through whole-genome screening of syndromic patients by array-CGH leads not only to the description of new syndromes, but also to the recognition of a broader spectrum of features for already described syndromes. Furthermore, on the technical side, we have significantly reduced the amount of reagents used and costs involved in the array-CGH protocol, without evident reduction in efficiency, bringing the method more within reach of centers with limited budgets. Copyright (c) 2006 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2006        PMID: 17124408     DOI: 10.1159/000095922

Source DB:  PubMed          Journal:  Cytogenet Genome Res        ISSN: 1424-8581            Impact factor:   1.636


  20 in total

1.  Use of array genomic hybridization technology for constitutional genetic diagnosis in Canada.

Authors:  Alessandra Mv Duncan; Bernard Chodirker
Journal:  Paediatr Child Health       Date:  2011-04       Impact factor: 2.253

2.  A case of 3q29 microdeletion syndrome involving oral cleft inherited from a nonaffected mosaic parent: molecular analysis and ethical implications.

Authors:  Aline L Petrin; Sandra Daack-Hirsch; Jamie L'Heureux; Jeffrey C Murray
Journal:  Cleft Palate Craniofac J       Date:  2010-05-04

3.  Implementation of chromosomal microarrays in a cohort of patients with intellectual disability at the Argentinean public health system.

Authors:  Lucía Daniela Espeche; Andrea Paula Solari; María Ángeles Mori; Rubén Martín Arenas; María Palomares; Myriam Pérez; Cinthia Martínez; Vanesa Lotersztein; Mabel Segovia; Romina Armando; Liliana Beatriz Dain; Julián Nevado; Pablo Lapunzina; Sandra Rozental
Journal:  Mol Biol Rep       Date:  2020-09-13       Impact factor: 2.316

4.  Value for money? Array genomic hybridization for diagnostic testing for genetic causes of intellectual disability.

Authors:  Dean A Regier; Jan M Friedman; Carlo A Marra
Journal:  Am J Hum Genet       Date:  2010-04-15       Impact factor: 11.025

5.  The 3q29 microdeletion syndrome: report of three new unrelated patients and in silico "RNA binding" analysis of the 3q29 region.

Authors:  Majed J Dasouki; Gerald H Lushington; Karine Hovanes; James Casey; Mereceds Gorre
Journal:  Am J Med Genet A       Date:  2011-05-27       Impact factor: 2.802

Review 6.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Authors:  David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter
Journal:  Am J Hum Genet       Date:  2010-05-14       Impact factor: 11.025

7.  Benign copy number changes in clinical cytogenetic diagnostics by array CGH.

Authors:  H Whitby; A Tsalenko; E Aston; P Tsang; S Mitchell; P Bayrak-Toydemir; C Hopkins; G Peters; D K Bailey; L Bruhn; A R Brothman
Journal:  Cytogenet Genome Res       Date:  2009-03-11       Impact factor: 1.636

8.  Genomic imbalances in neonates with birth defects: high detection rates by using chromosomal microarray analysis.

Authors:  Xin-Yan Lu; Mai T Phung; Chad A Shaw; Kim Pham; Sarah E Neil; Ankita Patel; Trilochan Sahoo; Carlos A Bacino; Pawel Stankiewicz; Sung-Hae Lee Kang; Seema Lalani; A Craig Chinault; James R Lupski; Sau W Cheung; Arthur L Beaudet
Journal:  Pediatrics       Date:  2008-12       Impact factor: 7.124

9.  Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1.

Authors:  A C V Krepischi-Santos; D Rajan; I K Temple; V Shrubb; J A Crolla; S Huang; S Beal; P A Otto; N P Carter; A M Vianna-Morgante; C Rosenberg
Journal:  Cytogenet Genome Res       Date:  2009-07-14       Impact factor: 1.636

10.  Clinical use of array comparative genomic hybridization (aCGH) for prenatal diagnosis in 300 cases.

Authors:  Ignatia B Van den Veyver; Ankita Patel; Chad A Shaw; Amber N Pursley; Sung-Hae L Kang; Marcia J Simovich; Patricia A Ward; Sandra Darilek; Anthony Johnson; Sarah E Neill; Weimin Bi; Lisa D White; Christine M Eng; James R Lupski; Sau Wai Cheung; Arthur L Beaudet
Journal:  Prenat Diagn       Date:  2009-01       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.